

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

DIVISIONAL OF SERIAL NO.

1430-287

09/545,002

APPLICANT

BONNEFOY et al

(Use several sheets if necessary)

FILING DATE

GROUP

September 29, 2003

1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 97/20926	6/1997	PCT			
WO 97/31946	9/1997	PCT			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Caput et al. "Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor α chain" J. Biol. Chem. 271:16921-16926 (1996)
	Minty et al. "Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses" Nature 362:248-250 (1993)
	Aman et al. "cDNA Cloning and characterization of the human interleukin 13 receptor α chain" J. Biol. Chem. 271:29265-29270 (1996)
	Hilton et al. "Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor" Proc. Natl. Acad. Sci. USA 93:497-501 (1996)
	Callard et al. "IL-4 and IL-13 receptors: Are they one and the same?" Immunology Today 17:108-110 (1996)
	George et al. "Current methods in sequence comparison and analysis, selected methods and applications" (Schlesinger, ed.) Alan R. Liss, pages 124-129 (1998)
	Ngo et al. "Computational complexity, protein structure prediction, and the Levinthal paradox - The protein folding problem and tertiary structure prediction" (Merz & LeGrand, eds.) Birkhäuser Boston, pages 491-495 (1995)
	Bowie et al. "Deciphering the message in protein sequences: Tolerance to amino acid substitutions" Science 247:1306-1310 (1990)
	Wells "Additivity of mutational effects in proteins" Biochemistry 29:8509-8517 (1990)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)